Biotron Limited Pink Sheet Today
| BITRF Pink Sheet | USD 0.01 -0.01 -50.00% |
Performance 0High 8 · Moderate | Odds Of Distress HighLow 41 · Elevated |
Biotron Limited trades at $0.005, supported by a 50% decrease for the day. Biotron reflects estimated distress probability of 41%, but due to its OTC and sub-dollar classification, model outputs may not fully represent underlying financial risk. Return data over the last 90 trading days classifies Biotron as moderate in terms of performance. The performance scores are measured across the period from February 9, 2026 to May 10, 2026. Learn more.
Less Correlated Symbols Follow Valuation Odds of Bankruptcy
Biotron Limited [BITRF] is a Pink Sheet which is traded between brokers over the counter. BITRF classifies itself in the Biotechnology industry (Healthcare sector). Biotron Limited sits in the micro-cap bucket with market capitalization close to $18.67 million relative to biotechnology companies. Useful market capitalization details here include about 901.94 million shares outstanding, enterprise value near $15.31 million, and operating in the Biotechnology industry. A negative net margin of 1.78% indicates the company is not currently profitable on a net income basis. Biotron is a research-driven pharmaceutical developer where revenue is driven by pipeline advancement, approvals, and patent-protected revenue. BITRF reported revenue of $1.56 million. Net Loss for the year was -$2.78 million with profit before overhead, payroll, taxes, and interest of $1.56 million. Biotron financial stability analysis Ownership Allocation Biotron shows a 14.13% of its outstanding shares held by insiders and 0.0% owned by institutional holders.
Check Biotron Ownership Details Check how we calculate scores
Pink Sheet Notable Updates
| Legal Name | Biotron Limited |
| Business Concentration | Biotechnology, Healthcare, (View all Sectors) |
Common Risk Profiles
| Mean Deviation | 29.54 | |||
| Standard Deviation | 121.41 | |||
| Variance | 14740.4 | |||
| Risk Adjusted Performance | 0.1091 |
Biotron Limited Against Markets
| NYA | 0.30 | ||||
| BITRF | 50.00 |
| Compare Correlations |
Investor Insights and Alerts
| Biotron Limited is way too risky over 90 days horizon | |
| Biotron Limited has some characteristics of a very speculative penny stock | |
| Biotron Limited appears to be risky and price may revert if volatility continues | |
| BITRF reported revenue of $1.56 million. Net Loss for the year was -$2.78 million with profit before overhead, payroll, taxes, and interest of $1.56 million. | |
| Biotron Limited has accumulated about $1.74 million in cash as of latest reporting with -$2.44 million of positive cash flow from operations. | |
| Roughly 14.0% of BITRF shares are held by company insiders |
Market Capitalization
Biotron Limited sits in the micro-cap bucket with market capitalization close to $18.67 million relative to biotechnology companies. Useful market capitalization details here include about 901.94 million shares outstanding, enterprise value near $15.31 million, and operating in the Biotechnology industry.Profitability
Profitability metrics test whether Biotron Limited is building real earning power or just reporting one-time accounting gains. The best read combines margin history with balance-sheet strength and pricing power under softer demand. BITRF has Profit Margin (PM) of -1.78%. Similarly, it shows Operating Margin (OM) of -1.78%.Technical Drivers
As of the 10th of May, Biotron prints 0.01 per share on the tape. Available indicator data includes Standard Deviation of 121.41, mean deviation of 29.54, and Risk Adjusted Performance of 0.1091. Market dynamics are evaluated through structured indicator analysis. Daily range variability typically expands at this level. Indicator dispersion is evaluated across similar market participants.Technical and Predictive Indicators
| Risk Adjusted Performance | 0.1091 | |||
| Market Risk Adjusted Performance | 25.71 | |||
| Mean Deviation | 29.54 | |||
| Coefficient Of Variation | 924.12 | |||
| Standard Deviation | 121.41 | |||
| Variance | 14740.4 | |||
| Information Ratio | 0.1083 | |||
| Jensen Alpha | 13.14 | |||
| Total Risk Alpha | 16.09 | |||
| Treynor Ratio | 25.7 | |||
| Maximum Drawdown | 1042.08 | |||
| Skewness | 7.97 | |||
| Kurtosis | 64.0 |
| Risk Adjusted Performance | 0.1091 | |||
| Market Risk Adjusted Performance | 25.71 | |||
| Mean Deviation | 29.54 | |||
| Coefficient Of Variation | 924.12 | |||
| Standard Deviation | 121.41 | |||
| Variance | 14740.4 | |||
| Information Ratio | 0.1083 | |||
| Jensen Alpha | 13.14 | |||
| Total Risk Alpha | 16.09 | |||
| Treynor Ratio | 25.7 | |||
| Maximum Drawdown | 1042.08 | |||
| Skewness | 7.97 | |||
| Kurtosis | 64.0 |
Forecast Models
Quantitative tools for Biotron Limited focus on observed patterns, which helps when markets move faster than research can update. Forecast models complement fundamental research by showing where price behavior supports or contradicts the thesis.Pink Sheet Overview, Methodology & Data Sources
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Headquarters are in 66 Hunter Street, Sydney, NSW, Australia, 2000. Recent market snapshot indicates market cap 18.67 million, P/B 23.61. As a micro-cap equity, Biotron is evaluated across valuation, solvency, and efficiency signals. Operating metrics are tied to how the market is pricing risk. Lower liquidity environments can sometimes affect short-term price stability.
Methodology
Unless otherwise specified, financial data for Biotron Limited is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biotron (USA Stocks:BITRF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Underlying inputs rely on public filings and market reference sources, including disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Values may reflect publication timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biotron Limited may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Be Your Own Money Manager
Optimization tools reveal whether capital allocated to Biotron Limited is being used efficiently relative to other opportunities in the same equity universe. When applied, optimization turns position sizing and rebalancing into measurable decisions rather than guesswork.
Did You Try This?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
More Resources for Biotron Pink Sheet Analysis
Financial ratios represent how different financial values are linked for Biotron. They summarize how financial performance connects to valuation.